Successful Grant Application! Trince received a VLAIO R&D grant to support activities for further developing its novel intracellular delivery technology towards clinical cell-based therapeutic applications.

The project runs until April 2025 and has three main objectives:

  1. Successful engineering of human T cells with large effector molecules (plasmids, mRNA and CRISPR/Cas9 RNPs) while preserving T cell fitness and therapeutic efficacy,
  2. Develop a prototype device for automated high-throughput transfection of T cells based on Trince’s proprietary photoporation technology and,
  3. Successful internal and external evaluation of the automated high-throughput prototype device.

We use cookies to analyze website traffic, optimize your browsing experience, and provide personalized content. You can choose which categories of cookies you wish to allow.

Privacy Preference Center